A bicuspid aortic valve (BAV) is the most common congenital heart valve defect, affecting approximately 1% to 2% of the general population. In a healthy heart, a tricuspid aortic valve features three pliable tissue flaps (cusps or leaflets) that open and close with every heartbeat to regulate oxygen-rich blood flowing from the left ventricle into the aorta. In individuals with BAV, two of these leaflets fuse together during fetal development in utero, leaving the valve with only two functional cusps.
This structural variation occurs two to three times more frequently in males than in females and carries a strong hereditary link. Because a two-leaflet valve cannot open as widely or close as tightly as a standard three-leaflet valve, it alters normal blood flow mechanics. Over decades, this turbulent blood flow places abnormal haemodynamic strain on both the valve tissue and the wall of the main artery, leading to three primary cardiovascular complications:
Most individuals born with a bicuspid aortic valve experience no noticeable symptoms during childhood or early adulthood because the heart initially compensates well for mild turbulence. Clinical manifestations typically surface between the ages of 40 and 60 as progressive calcium build-up stiffens the valve leaflets and restricts blood flow out of the heart. Once severe aortic stenosis develops, patients commonly present with a classic triad of warning signs alongside secondary symptoms:
Confirming a bicuspid aortic valve diagnosis and preventing irreversible heart muscle damage requires structured imaging and lifelong congenital heart valve defect monitoring. Cardiologists rely on a stepwise diagnostic protocol to track both leaflet function and aortic dimensions over time:
No oral medication can reverse leaflet calcification or cure a mechanically narrowed bicuspid valve. When aortic stenosis or regurgitation becomes severe—or if the ascending aorta dilates to a high-risk threshold (typically 50 mm to 55 mm depending on clinical risk factors)—definitive intervention is required. In Malaysia, treatment decisions are guided by a multidisciplinary Heart Team comprising interventional cardiologists, cardiothoracic surgeons, and cardiac imaging specialists.
Historically, open-heart Surgical Aortic Valve Replacement (SAVR) was the sole standard of care. However, advancements in Transcatheter Aortic Valve Implantation (TAVI)—pioneered in Asia by Institut Jantung Negara (IJN) in 2009 and widely performed at specialized centres like Cardiac Vascular Sentral Kuala Lumpur (CVSKL)—now provide a minimally invasive alternative for appropriately selected patients.
| Clinical & Planning Factor | Transcatheter Aortic Valve Implantation (TAVI) | Surgical Aortic Valve Replacement (SAVR) |
| Procedure Approach | Minimally invasive; a collapsible bioprosthetic valve is delivered via a catheter, usually through the femoral artery in the groin, without stopping the heart. | Open-heart surgery via a full sternotomy or minimally invasive mini-thoracotomy; requires a heart-lung bypass machine to excise the native valve. |
| Anatomical Suitability for BAV | Suitable for selected BAV patients (often older or intermediate-to-high surgical risk) with favourable calcium distribution and normal aortic root dimensions. | Preferred gold standard for younger patients, heavily or asymmetrically calcified bicuspid valves, or when concurrent ascending aorta aneurysm repair is needed. |
| Valve Options & Durability | Uses expandable tissue (bioprosthetic) valves. Long-term durability data spans 10–15 years; future valve-in-valve procedures may be considered. | Offers a choice between mechanical valves (lasting 20–30+ years, requiring lifelong warfarin blood thinners) or biological tissue valves (lasting 10–15 years). |
| Hospital Stay & ICU Recovery | Shorter hospitalisation, typically 2 to 4 days, with minimal intensive care stay. | Longer inpatient monitoring, typically 5 to 10 days including 1 to 3 days in the Intensive Care Unit (ICU). |
| Full Recovery Timeline | Rapid return to daily activities within 1 to 2 weeks with minimal post-procedural pain. | Gradual recovery over 6 to 12 weeks to allow the breastbone (sternum) and chest muscles to heal fully. |
| Estimated Cost in Malaysia (Secondary Context) | RM 70,000 – RM 160,000+ at IJN Private or private hospitals, driven primarily by the specialised transcatheter valve device. | RM 50,000 – RM 100,000+ in private wings or private tertiary hospitals, varying by valve type, ICU stay, and concurrent root repair. |
Note on clinical suitability: While TAVI offers a much faster recovery, bicuspid valves present unique anatomical challenges compared to standard three-leaflet valves, including an elliptical opening and asymmetrical calcium nodules. If your ascending aorta is also dangerously enlarged, open surgery (SAVR combined with an aortic root graft) remains the safer, comprehensive solution because a catheter-based valve only addresses the valve opening itself.
While you cannot alter the congenital two-leaflet structure of a bicuspid aortic valve, proactive medical and lifestyle management helps slow haemodynamic wear and protect the ascending aorta from rapid expansion or infection:
Managing a congenital valve condition effectively requires choosing the right sub-specialist and understanding how Malaysia’s healthcare referral pathways work. Depending on your stage of disease, your care may involve an Adult Congenital Heart Disease (ACHD) cardiologist for long-term surveillance, an interventional cardiologist certified in structural heart procedures (such as TAVI), or a cardiothoracic surgeon experienced in aortic root and valve reconstruction.
Malaysia is home to several high-volume tertiary cardiac centres equipped with dedicated Heart Teams:
When preparing for your first specialist consultation, compile your complete medical history, including previous echocardiogram reports (especially any baseline measurements of your aortic root diameter), recent blood test panels, ECG strips, and current medications.
If you are seeking subsidised care through the Ministry of Health (MOH) public hospital network or the public wing of IJN, obtain a formal referral letter (Surat Rujukan) from a government Klinik Kesihatan or a general hospital medical officer. Civil servants, government pensioners, and eligible low-income patients may qualify for government funding or medical aid schemes for valve prostheses. Conversely, if you opt for faster scheduling via IJN Private or a private hospital, verify your medical insurance policy terms in advance to arrange a Guarantee Letter (GL). Keep in mind that while private medical cards often cover acquired heart diseases, congenital heart defects may be subject to specific policy exclusions or waiting periods unless explicitly covered under your plan.
Whether a bicuspid aortic valve can be repaired depends on the primary problem. If the valve is heavily calcified and narrowed (aortic stenosis), the stiffened leaflets cannot be reshaped and require replacement via open surgery (SAVR) or a catheter procedure (TAVI). However, younger patients who have a leaky valve (aortic regurgitation) with pliable, non-calcified leaflets may be candidates for surgical aortic valve repair at specialised cardiac centres.
No, TAVI is not suitable for every BAV patient. While newer-generation transcatheter valves have expanded TAVI to many bicuspid patients, suitability depends heavily on your age, surgical risk profile, pattern of leaflet calcification, and whether your ascending aorta is enlarged. Younger patients or those requiring simultaneous repair of an ascending aortic aneurysm are typically advised to undergo traditional open-heart surgery for superior long-term durability.
Total hospital bills for heart valve replacement vary based on several clinical factors: your admission category (government-subsidised public patient versus private self-paying or insured patient), the type of prosthetic valve selected (mechanical valve, surgical tissue valve, or specialised TAVI catheter device), the length of Intensive Care Unit (ICU) stay, and whether additional procedures like coronary bypass or ascending aorta root replacement are performed during the same operation.
Adults with a mild, stable bicuspid aortic valve and normal aortic dimensions generally need a surveillance echocardiogram every 2 to 3 years. If imaging shows moderate-to-severe valve narrowing, significant backward leakage, or an ascending aorta diameter wider than 40 to 45 mm, cardiologists typically increase monitoring frequency to every 6 to 12 months.
Bicuspid aortic valve disease runs in families, though it does not affect every child. Clinical studies show that first-degree relatives—parents, siblings, and children—have an approximately 7% to 10% chance of also having a bicuspid valve or aortic enlargement. Because the condition rarely causes symptoms in youth, cardiologists recommend a one-time baseline screening echocardiogram for all immediate family members.
This article is for reference only; the actual coverage terms are subject to the policy.
This article is for reference only and is not medical advice. Please consult a registered doctor if you have any concerns.
© 2026 Bowtie Life Insurance Company Limited. All rights reserved.